Amendments to the Claims:

Rewrite the claims as set forth below. This listing of claims replaces all prior versions and listings of claims in the application:

1. (Currently Amended) A composite sheet, which is applied to the surface of skin for delivering a therapeutic agent to the skin comprising:

a flexible porous polymer foam material for holding and releasing the therapeutic agent,

a polymer enrobing material which is in contact with the skin and encapsulates the polymer foam material and holds and releases the agent, and

a plurality of microchannels passing through the polymer enrobing material and polymer foam material for holding and releasing the agent, wherein the microchannels are loaded with therapeutic agent, and

~~wherein~~ the therapeutic agent is ~~dispersed~~ delivered from the microchannels into the porous polymer foam material and polymer enrobing material for ~~distribution~~ release to the skin.

2. (Previously Presented) The composite sheet according to claim 1 wherein the sheet is capable of releasing the therapeutic agent for a period of about 0 to about 14 days.

3. (Previously Presented) The composite sheet according to claim 1 wherein the porous foam material has open face pores for holding and releasing the therapeutic agent having a diameter of about 200 to about 300 microns.

4. (Previously Presented) The composite sheet according to claim 1 wherein the porous polymer foam material is selected from the group consisting of polyurethane, polyvinylacetate, polyvinyl alcohol, polyethylene, and silicone.

5. (Previously Presented) The composite sheet according to claim 1 wherein the polymer enrobing material which encapsulates the porous polymer foam material is selected from the group consisting of silicone, hydrogels, ethylene-vinyl acetate and polyurethane elastomers.

6. (Currently Amended) The composite sheet according to claim 1 wherein the sheet has a first side and a second side which contacts the skin with the microchannels, passing therethrough for holding and releasing the therapeutic agent into the porous polymer foam material and polymer enrobing material for ~~distribution~~ release to the skin.

7. (Original) The composite sheet according to claim 6 having a removable rigid polymer strip, which is applied to the first and second sides for retaining the therapeutic agent in the microchannels prior to application of the sheet to the skin.

8. (Cancelled)

9. (Currently Amended) The compound sheet according to claim 1 wherein the therapeutic agent is selected from the group consisting of therapeutic oils, plant extracts, animal extracts, drugs, vitamins, minerals, hormones, antioxidants, Vitamin E, Vitamin C, emu oil, aloe vera, silver sulphadiazine, polymixine B, fusidic acid, platelet-derived growth factor, corticosterioids and interferon.

10–15. (Cancelled)

16. (Previously Presented) The composite sheet according to claim 1 wherein the composite sheet is capable of releasing the therapeutic agent for a period of about 14 to about 30 days.

17–18. (Cancelled)

19. (Previously Presented) The composite sheet according to claim 8 wherein the porous polymer foam material is polyurethane, and wherein said polyurethane is hydrophilic.

20. (Previously Presented) The composite sheet according to claim 1 wherein the composite sheet is capable of releasing the therapeutic agent for a period of about 30 days.

21. (Cancelled)

22. (Currently Amended) A method of delivering a therapeutic agent to the skin comprising loading one or more therapeutic agents into microchannels passing through a flexible porous polymer foam material, and a polymer enrobing material which is in contact with the skin and encapsulates the polymer foam material so that the therapeutic agent ~~may be~~ is dispersed from the microchannels into the flexible porous polymer foam and polymer enrobing material, and thereby ~~distributing~~ releasing the therapeutic agent to the skin.

23. (Previously Presented) The method according to claim 22 wherein the porous polymer foam material is selected from the group consisting of polyurethane, polyvinylacetate, polyvinyl alcohol, polyethylene, and silicone.

24. (Previously Presented) The method according to claim 22 wherein the polymer enrobing material which encapsulates the porous polymer foam material is selected from the group consisting of silicone, hydrogels, ethylene-vinyl acetate and polyurethane elastomers.

25. (Previously Presented) The method according to claim 22 wherein the sheet has a first side and a second side which contacts the skin with the microchannels, passing

therethrough forming an area for holding and directly releasing the therapeutic agent onto or into the skin and into the porous polymer foam material and polymer enrobing material for subsequent release to the skin.

26. (Previously Presented) The method according to claim 22 wherein the plurality of microchannels pass through the polymer foam material and polymer enrobing material for dispersing the therapeutic agent for distribution on the skin.

27. (Currently Amended) The method according to claim 22 wherein the therapeutic agent is selected from the group consisting of therapeutic oils, plant extracts, animal extracts, drugs, vitamins, minerals, hormones, antioxidants, Vitamin E, Vitamin C, emu oil, aloe vera, silver sulphadiazine, polymixine B, fusidic acid, platelet-derived growth factor, corticosterioids and interferon.

28. (New) A composite sheet, which is applied to the surface of skin for delivering a therapeutic agent to the skin comprising:

a flexible porous polymer foam material for holding and releasing the therapeutic agent,

a polymer enrobing material which is in contact with the skin and encapsulates the polymer foam material and holds and releases the agent, and

a plurality of microchannels passing through the polymer enrobing material and polymer foam material for holding and releasing the agent, wherein the microchannels are loaded with therapeutic agent for releasing the therapeutic agent to the skin.

29. (New) The composite sheet according to claim 28 wherein the sheet is capable of releasing the therapeutic agent for a period of about 0 to about 14 days.